UV spectrophotometric determination of chlorthalidone in tablet dosage form by using single point standardization method

Abstract

The current research endeavors to elucidate the creation of an uncomplicated, highly sensitive, swift, precise, and cost-effective UV-accepted spectrophotometric method for the quantitative assessment of Chlorthalidone. This is achieved through the utilization of a visible spectrophotometric approach employing single-point standardization and calibration plot methods, for pharmaceutical dosage forms. The equipment employed includes a double-beam UV-visible spectrophotometer, specifically the Shimadzu Model UV1800, with 1cm quartz cells and 0.2 M Sodium hydroxide serving as the solvent. Notably, an absorption maximum is identified at 219 nm. The developed method strictly adheres to Beer’s law. In the case of single-point standardization, the percentage of Chlorthalidone detected falls below the labeled claimed limit. Simultaneously, the tablet formulation is subjected to a percentage purity test using the calibration plot method, revealing that the observed quantity of Chlorthalidone is below the labeled content. This suggests a potential discrepancy in the marketed product of Chlorthalidone, indicating a probable deficiency in the therapeutic effect of the formulation due to the lower amount of Chlorthalidone present. The overall efficacy of the product hinges on the quality assurance of its constituents.